Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cara Therapeutics, Inc.    CARA

CARA THERAPEUTICS, INC.

(CARA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Cara Therapeutics : and Vifor Pharma License Agreement Presentation

10/20/2020 | 08:55am EST

Expanded Cara/Vifor Pharma U.S. Commercial Collaboration

October 2020

1

Forward Looking Statements

  • Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward- looking statements include statements concerning plans, strategies and expectations for the future, including statements concerning the potential market opportunity for IV KORSUVA and Oral KORSUVA, the ability of KORSUVA to address a significant unmet need, the potential timing of regulatory submissions for and approval of IV KORSUVA, the potential commercialization of IV KORSUVA by Vifor (International) Ltd. ("Vifor Pharma"), the potential advantages of entering into an agreement with Vifor Pharma, the potential equity investment, milestone and profit- sharing payments payable to Cara Therapeutics, Inc. (the "Company") pursuant to the agreement, and the Company's expected cash reach. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Some of these risks and uncertainties include, but are not limited to, those related to the receipt of data sufficient to support regulatory submissions and required regulatory approvals of KORSUVA, and uncertainties regarding the rate and degree of market acceptance of IV KORSUVA, if approved for marketing, as well as those risks and uncertainties described more fully in the Company's filings with the Securities and Exchange Commission, including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this presentation speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

2

U.S. Potential KORSUVA Opportunity: IV & Oral

KORSUVA Injection

0.5 Million Hemodialysis

~40%

moderate-severe

CKD-aP

~60%

experience pruritus

Oral KORSUVA

12 Million* Atopic Dermatitis

~87% to 100%

experience pruritus

7 Million* CKD (Stage III-V)

~25 to 30%

experience pruritus

7 Million* Liver Disease

~30 to 40%

experience pruritus

3 * Diagnosed: IQVIA

US Market Opportunity for KORSUVA™ Injection For CKD-associated

Pruritus (CKD-aP) in Dialysis Patients

60%

of ESRD patients have pruritus2,3

>500K1

patients on dialysis

  • Serious intractable systemic pruritus
  • CKD-aPassociated with worsening Quality of Life (QoL) sleep disturbance, depressed mood/anxiety, socialization
  • Increased mortality risk

KORSUVA™ granted Breakthrough Therapy Designation for CKD-aP

  • Significant unmet need
  • No FDA approved therapies

~40%

have moderate to severe pruritus

Phase 3 Program complete

  • NDA submission - Q4, 20204
  • Commercial launch - 20214

1. National Kidney Foundation

2. Pisoni RL, Wikstrom B, Elder SJ, et al. Nephrol Dial Transplant. 2006;21:3495-3505.

3. Ramakrishnan et al. International Journal of Nephrology and Renovascular Disease. 2014:7 1-12

4

4. Current projected timeline

KORSUVA Injection: U.S. Commercial Strategy

  • Employ Vifor Established Nephrology Commercial Organization
    200 sales FTEs: Mircera, Velphoro, Venafer
    Existing relationships with US LDOs, MDOs and IDOs Established market access team
    Existing supply chain organization
  • Leverage Existing Cara/Vifor Synergies From Ongoing Collaboration
    Global brand development
  • Significant Cost Savings From Reduced Cara Commercial Build-Out

5

Cara/Vifor Commercialization Agreement: Summary Terms

(Ex-Fresenius Medical Care Clinics)

  • Up-Front:$150M ( $100M Cash/ $50M Equity)
  • U.S. Regulatory Approval Milestone: $50M Equity
  • U.S. Market Profit Split: Cara 60%: Vifor 40%

(Ex-FMC Clinics: Vifor Promotion1)

  • U.S Commercial Sales Milestones: $240M

1. FMC Clinics Profit Split: Cara 50%: VFMCRP 50% - 2018 Cara and Vifor/Fresenius License Agreement

6

Cara/Vifor Commercialization Agreement: Summary Terms

  • Licensed Product: Korsuva Injection (IV CR845)
    Treatment of CKD-aP in dialysis patients
  • Licensed Territory: US - Ex-Fresenius Medical Care Clinics1
  • Field: Treatment of Pruritus in Hemo/Peritoneal Dialysis Patients

1. FMC Clinics Profit Split: Cara 50%: VFMCRP 50% - 2018 Cara and Vifor/Fresenius License Agreement

7

Cara/Vifor Commercialization Agreement

Key Elements

  • Ideal Strategic US Commercialization Partner for Korsuva Injection
    Established dedicated nephrology-focused salesforce
  • Cara Retains Commercial Up-Side for Korsuva Injection
  • Cara 60%:Vifor 40% profit-sharing agreement
  • Strengthens Cara Balance Sheet in Minimally-Dilutive Manner
  • Cost savings resulting from reduced projected commercial spend
  • Focus internal resources on Oral Korsuva Phase 3 programs
  • Extends cash runway into 2023

8

Disclaimer

CARA Therapeutics Inc. published this content on 20 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 October 2020 12:54:04 UTC


© Publicnow 2020
All news about CARA THERAPEUTICS, INC.
11/11CARA THERAPEUTICS : to Present at Multiple Upcoming Investor Conferences
AQ
11/11Cara Therapeutics to Present at Multiple Upcoming Investor Conferences
GL
11/09CARA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
11/09CARA : 3Q Earnings Snapshot
AQ
11/09CARA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financi..
AQ
11/09CARA THERAPEUTICS : Reports Third Quarter 2020 Financial Results
AQ
11/09Cara Therapeutics Reports Third Quarter 2020 Financial Results
GL
11/02CARA THERAPEUTICS : to Announce Third Quarter 2020 Financial Results on November..
AQ
11/02Cara Therapeutics to Announce Third Quarter 2020 Financial Results on Novembe..
GL
10/27CARA THERAPEUTICS : SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milest..
PR
More news
Financials (USD)
Sales 2020 65,1 M - -
Net income 2020 -53,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -10,3x
Yield 2020 -
Capitalization 745 M 745 M -
Capi. / Sales 2020 11,4x
Capi. / Sales 2021 26,2x
Nbr of Employees 76
Free-Float 83,9%
Chart CARA THERAPEUTICS, INC.
Duration : Period :
Cara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 32,63 $
Last Close Price 14,95 $
Spread / Highest target 168%
Spread / Average Target 118%
Spread / Lowest Target 20,4%
EPS Revisions
Managers
NameTitle
Derek T. Chalmers President, Chief Executive Officer & Director
Thomas Reilly Chief Financial & Accounting Officer
Frèdèrique Menzaghi Chief Scientific Officer, Senior VP-R&D
Joana Goncalves Chief Medical Officer
Martin A. Vogelbaum Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARA THERAPEUTICS, INC.-7.20%745
IQVIA HOLDINGS INC.9.26%32 365
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 070
PRA HEALTH SCIENCES, INC.-0.14%7 120
SYNEOS HEALTH, INC.12.08%6 932
NOVAVAX, INC.2,477.89%6 427